



Cure InSight

Cure Parkinson's Spring 2023 Newsletter

Professor Anthony Schapira
ASPro-PD

The International Link
Clinical Trials program

VAN ANDEL
INSTITUTE



INTERNATIONAL LINKED CLINICAL TR

WELCOME

To the spring edition of our newsletter.

THE LATEST

Read more about how a humble cough medicine is entering a phase 3 trial as a potential treatment for Parkinson's.

FUNDRAISER OF THE YEAR

We announce our 2022 Fundraiser of the Year and share ideas of an exciting summer of fundraising.

ART FOR PARKINSON'S

Find out how Cure³, a unique art exhibition, is raising substantial funds for Parkinson's research.



Contents

OUR VISION

A world free from Parkinson's.

OUR MISSION

We fund and facilitate research that has the potential to cure Parkinson's. We're working with urgency to find new treatments that can slow, stop or reverse the condition.

ABOUT US

Welcome from our CEO 3

OUR RESEARCH

Ambroxol and Parkinson's 4-5
Our research impact 6
Pipeline research programme 7
2023 research highlights 8-9

OUR FUNDRAISING

Ambroxol appeal 10-11
Cure³ 2023 12
Summer fundraising 13
Running for a cure 14
Events calendar 15
Fundraiser of the Year 16
Corporate partnerships 17
Trusts and foundations 18
Leave a legacy to Cure Parkinson's 19

Look out for QR codes dotted throughout our newsletter. To use them point your phone's camera at the QR code so you can see it on the screen. Tap on the notification that appears to open the link in your web browser and be taken to our website to find out more about our work.



VISIT OUR WEBSITE

Cover photo: Professor Anthony Schapira presenting at Cure Parkinson's spring Research Update Meeting

Welcome from our CEO

A warm welcome to our spring edition of Cure InSight. Following a busy start to the year, 2023 is already proving to be one of progress for our research.

I am delighted to bring you news that the phase 3 trial of ambroxol, called ASPro-PD, will begin recruiting this year. The trial is the result of a collaboration across the Parkinson's community: your support has enabled us to commit £2.2 million to fund the trial and we are joined by our strategic partners Van Andel Institute (VAI) and the John Black Charitable Foundation, as well as the Parkinson's Virtual Biotech, the drug discovery and development arm of Parkinson's UK, who are each committing £1.1 million. It is hoped the trial will determine if ambroxol can slow the progression of Parkinson's – something not possible with current treatments.

Ambroxol is among several drugs prioritised for clinical trial through our International Linked Clinical Trials programme (iLCT), an initiative advancing multiple treatments into clinical trial for Parkinson's. In a wider-ranging development, we are now also expanding the iLCT programme to progress early-stage research with clear clinical potential. Headed up by Dr Leah Mursaleen, our iLCT pipeline research initiative aims to take even more treatments into clinical trial urgently, by actively seeking critical pre-clinical evidence on certain iLCT candidates, to accelerate the passage to clinic.

We are also happy to announce the renewal of our co-funding agreement with VAI for a further three years, supporting additional collaborative Parkinson's research. This will enable the launch of more clinical trials of potentially disease-modifying drugs, identified through the iLCT process. Read more about this on page 5.

Following a full calendar of activity in the last year, and after the disruption caused by the Covid-19 pandemic, it is pleasing that the



Pictured above: Will Cook taking part in the 2022 TCS New York City Marathon for Cure Parkinson's

charity put more funds into Parkinson's research in 2022 than any previous year - directing £5.6 million to ground-breaking projects. Of course, none of this would be possible without your support. Despite all the challenges of recent years, our vital work to find a cure continues to move forward.

And finally, also in this edition, we bring you news of how our extraordinary Cure³ art exhibition is breaking new ground in the charity art world, all to raise funds for Parkinson's research ... we announce our 2022 Fundraiser of the Year ... and we bring you ideas for a summer of fundraising activities.

Will Cook, CEO, Cure Parkinson's

Ambroxol and Parkinson's

Could ambroxol, a humble cough medicine, be a possible breakthrough in treating Parkinson's? Ambroxol has been commonly used to treat coughs and sore throats across Europe since 1973. Following promising results reported at phase 2 in 2020 testing ambroxol in people with Parkinson's, a large-scale phase 3 clinical trial of ambroxol will be starting this year.

Starting in 2023, the ASPro-PD trial (Ambroxol to Slow Progression in Parkinson) is a world-first phase 3 trial aimed at establishing ambroxol's potential to slow the progression of Parkinson's.

Led by Professor Anthony Schapira at University College London (UCL), the trial will involve 330 people with Parkinson's across 10-12 clinical centres in the UK. The effectiveness of ambroxol will be measured by its ability to slow the progression of Parkinson's using scales that measure quality of life and movement over two years. Preparations for recruitment of trial participants have already started.

// Scientifically speaking, this is the most excited I have been about one of our studies. It is testing a very specific idea about the underlying biology of Parkinson's. A huge amount of work has gone into the development of the study. The phase 2 trial provided encouraging results, and now we are set to determine if taking this agent - ambroxol - can actually slow the progression of Parkinson's. It is a fascinating project, which we hope will have major benefits for the Parkinson's community.

Dr Simon Stott, Director of Research, Cure Parkinson's



The John Black Charitable Foundation



Ambroxol is just one of a number of drugs prioritised by the International Linked Clinical Trials (iLCT) programme, created and operated by Cure Parkinson's and Van Andel Institute (VAI). The iLCT mission is to slow, stop and reverse the progression of Parkinson's; it aims to significantly reduce the time to bring disease-modifying treatments to clinic for the Parkinson's community by testing promising drugs that already have extensive safety data and, in some cases, have been approved by regulators for other medical conditions.

The ASPro-PD phase 3 trial is a big step forward in the search to find new treatments for Parkinson's. Once it is underway this trial will be one of only six phase 3 trials on public record of potentially disease-modifying drugs in Parkinson's, worldwide.

Cure Parkinson's has been instrumental in getting two of the six phase 3 clinical trials to assess drugs to modify the progression of Parkinson's underway. Through our efforts within the iLCT programme and in our fundraising we are determined to increase this number of trials significantly in the next few years - we won't stop until a cure is found.

We are proud to receive co-funding for the ASPro-PD trial from Van Andel Institute in the USA, and UK charities the Parkinson's Virtual Biotech, the drug discovery and development arm of Parkinson's UK and The John Black Charitable Foundation. Please see page 8 for more details.

Everyone expressing an interest in taking part in the ASPro-PD trial will be genetically screened, via PD Frontline, as part of the trial selection criteria. We are particularly interested to hear from people who have been diagnosed with Parkinson's in the last six years and are under the age of 75.

To register your interest in taking part, please visit cureparkinsons.org.uk/research/amtakepart or use the QR code below.



REGISTER YOUR INTEREST



If you would like to know more about ambroxol and Parkinson's we have created a short animated explainer video which is available to view on our website at cureparkinsons.org.uk/ambroxol-and-parkinsons or via the QR code below.



WATCH OUR ANIMATION



Pictured above: Cure Parkinson's CEO Will Cook and Van Andel Institute's Chief Strategic Officer Jerry Callahan

Partnership funding agreement between CP and VAI for iLCT programme is renewed

Cure Parkinson's and Van Andel Institute (VAI) are delighted to announce that their co-funding agreement has been renewed for a further three years. The agreement pledges USD \$4.5 million in match-funding to Parkinson's research, strengthening an already long-standing partnership. This funding will support the iLCT initiative, that aims to develop new potentially disease-modifying Parkinson's treatments.

Since iLCT's inception in 2012, Cure Parkinson's and VAI have ensured the initiative continues to grow, as more clinical trials of potentially disease-modifying drugs are launched within the programme. Each side match-funds the other with contributions to trials. The 2023 agreement extends this effort for three years to the extent of \$4.5 million of match-funding, and also proposes collaborative fundraising initiatives.

Since the programme was launched, over 4,700 people have taken part in iLCT trials. 21 trials are ongoing with many more drugs in the pipeline.

Our research impact

Last year, Cure Parkinson's produced a report on the impact of our research funding to understand how it has affected the Parkinson's research field, what has changed over time and where we might improve in the future.

This analysis is an opportunity to take stock of what Cure Parkinson's has achieved over the last 18 years and how we can improve in the future to accelerate the search for a cure.

Since the charity's inception to the end of 2022, Cure Parkinson's has committed more than £16 million of funding to over 72 different projects.

Whilst these projects all aim to slow, stop or reverse the progress of the disease, the stage of research varies; some are pre-clinical (earlier, lab-based projects), some clinical (where the potential treatment is tested in people with Parkinson's) and some looking at infrastructure to accelerate the process itself. The trend of our research over time has shifted towards a more clinical focus; more people with Parkinson's are now involved with our research and benefit from potential treatments early.

159 potential treatments

evaluated by the iLCT committee



21 active and 20 completed trials

of iLCT evaluated potential treatments



4,700 people

have taken part in iLCT trials since the programme was launched in 2012



17 countries

across the globe testing iLCT potential treatments for Parkinson's



Alongside increasing numbers of funded projects, more of our research is published which contributes to the impact seen within scientific and wider communities. Our funded research is being cited in the media and other academic literature more and more each year.

More than 30 different therapeutic approaches have been researched through Cure Parkinson's funding. 65% of these have been evaluated by Cure Parkinson's International Linked Clinical Trials programme (iLCT) and 71% remain of interest as a potential Parkinson's treatment. 32% of potentially curative treatments have moved into a subsequent stage of research since funding and, whilst it is encouraging to have so many of interest, this highlights a key question: how can we proactively accelerate the process from the lab into clinical trial, and then make them accessible to people with Parkinson's sooner?

Pipeline Research programme

In an effort to speed up the background research needed to evaluate and progress more drugs through the International Linked Clinical Trials (iLCT) programme into clinical trial testing, Cure Parkinson's has set up the iLCT research pipeline. Heading this up is Dr Leah Mursaleen who explains more about the initiative.



Pictured above: Dr Leah Mursaleen, Head of Pipeline Research at Cure Parkinson's

on funding the additional research required to make these potential treatments trial ready in the shortest possible time.

// In my new role as Head of Pipeline Research I am really excited to be focusing on speeding up and driving forward early-stage research to ensure that more potentially disease-modifying treatments are ready to be taken into clinical trials for Parkinson's as soon as possible.

Dr Leah Mursaleen, Head of Pipeline Research, Cure Parkinson's

Each year our iLCT programme ranks a number of potentially disease-modifying treatments based on whether they are ready to be taken into clinical trial for Parkinson's. Amongst those that are not prioritised to move into trial immediately, are some that the expert iLCT committee believe show great potential however, they require further research before being tested in people with Parkinson's. This could be additional lab work to understand how the drug effects models of Parkinson's, research into the best dose to use for Parkinson's or analysing real world data from other disease areas to support the rationale for moving into Parkinson's trials.

As Head of Pipeline Research, I've been tasked with driving forward this research, to move more potential treatments into clinical trials sooner. In addition to our usual quarterly research grant funding calls, we've set up a new pipeline research funding programme focused solely

The point of this programme is urgency. We want to make sure that treatments with potential to alter the progression of Parkinson's are being actively pursued in the early stages so we can get more clinical trials underway and get closer to delivering actual treatments for people living with Parkinson's.

The first iLCT pipeline project was approved for funding in February. It is focused on testing three therapeutic agents previously evaluated by the iLCT committee – benfotiamine (a form of thiamine), methylcobalamin (a form of vitamin B12) and ibuprofen (a non steroidal anti-inflammatory drug) in models of Parkinson's. We look forward to learning the results in autumn 2024 to inform whether these potential treatments can move forward into clinical trials.

2023 research highlights

With clinical trial results expected and major new projects being initiated, 2023 is shaping up to be an exciting year for research with the potential to slow, stop or reverse Parkinson's.

Expected trial results

Diabetes medicines and Parkinson's: GLP-1 receptor agonists are a class of medication used to treat diabetes; more recently these drugs have been the focus of trials to repurpose them for Parkinson's and a number of them have been prioritised through Cure Parkinson's iLCT programme.

Although the phase 3 exenatide trial is still ongoing in the UK, Cure Parkinson's is looking forward to the formal results from the lixisenatide trial in France and Neuraly's trial results of NLY01, as these studies will add to the increasing amount of data for this important line of research.

UDCA: Data from laboratory trials using the liver drug UDCA to treat models of Parkinson's, indicated that it may rescue, recuperate or regenerate nerve cells (neurons). Cure Parkinson's co-funded the phase 2 clinical trial of UDCA in people with Parkinson's – the UP-Study. This was a small clinical trial primarily focused on assessing the safety and tolerability of the drug, as well as some biomarkers – samples taken from the participants.

We are looking forward to the formal presentation of these trial results and hope that they will herald a much larger study assessing the efficacy of UDCA in slowing the progression of Parkinson's – watch this space for more news of UDCA later in the year.

Opportunities to Engage with Research

Research Update Meeting: Our spring Research Update Meeting saw fantastic presentations from guest speakers Professor Roger Barker from University of Cambridge on the latest stem cell research to an amroxol update and panel discussion with Professor Anthony Schapira from University College London. Professor Schapira was joined by ASPro-PD trial manager Mairead Cullen, Cure Parkinson's CEO Will Cook and Parkinson's UK's CEO Caroline Russell and Director of Research David Dexter. Rewatch the presentations on our website at cureparkinsons.org.uk/spring-update-2023 or use the QR code below.



REWATCH HERE

Journal of Parkinson's Disease, Edinburgh University and Cure Parkinson's webinar series: We are delighted to see a return of this quarterly webinar series, with Edinburgh University's Professor Tilo Kunath as chair. Rewatch our latest webinar where Professor Kunath and an expert line-up of panelists discuss the topic of Exercise and Motivation. Please visit cureparkinsons.org.uk/webinars or use the QR code below to watch again or sign up to join our next webinar on 7 June where we'll be discussing Clinical trials targeting alpha-synuclein.



FIND OUT MORE

The World Parkinsons Congress: From the 4-7 July, World Parkinson Congress will be held in Barcelona, Spain. This is a triennial international event that brings together people with Parkinson's, care partners, basic scientists, clinical researchers, healthcare professionals, and other stakeholders. With a plethora of lectures and activities on every aspect of Parkinson's, this is an important meeting in our diary and Cure Parkinson's is co-organising the Clinical Research Village. Do consider coming along to join and be part of this very special event. Please visit cureparkinsons.org.uk/wpc-2023 or use the QR code below to find out more.



JOIN THE EVENT



NOMINATE

Tom Isaacs Award: Nominate a researcher who has had the greatest impact on the lives of people living with Parkinson's and/or has involved people with Parkinson's in a participatory way in their work. Previous winners on the Tom Isaacs Award Wall of Fame include Professor Tom Foltynie, Professor Bas Bloem, Dr Simon Stott, Professor Tilo Kunath, Professor Caroline Tanner, Professor Camille Carroll, Dr Michael Okun, Dr Ray Dorsey and Professor Patrik Brundin. Please visit cureparkinsons.org.uk/for-researchers/the-tom-isaacs-award/ or use the QR code below to find out more and nominate.



Will you help us fund the Ambroxol to Slow Progression in Parkinson (ASPro-PD) trial?

Ambroxol has been commonly used to treat coughs and sore throats across Europe since 1973.

Now, a clinical trial of ambroxol called 'Ambroxol to Slow Progression in Parkinson', or the 'ASPro-PD' trial, will begin. This is a large phase 3 clinical trial to determine if ambroxol can slow the progression of Parkinson's – something no other treatment can currently do.

This trial will cost £5.5 million, which is being funded by Cure Parkinson's alongside its strategic partners, Van Andel Institute (VAI) and the John Black Charitable Foundation, and by the Parkinson's Virtual Biotech, the drug discovery and development arm of Parkinson's UK.

Cure Parkinson's is committing to fund £2.2 million of the total cost, with the other funders contributing £1.1 million each. Thanks to your support to date, we have just £895k of dedicated funding left to raise within our £2.2 million commitment.

By supporting clinical trials for Parkinson's research, we can work towards improving the lives of those affected by the disease and ultimately finding a cure.

This trial is only possible due to your support; please consider making a donation dedicated towards the ambroxol phase 3 trial now.




Pictured above: Bev Maydon, Cure Parkinson's supporter

// Knowing that researchers are getting so close to a breakthrough is exciting. Not only would this make a real difference to the lives and hopes of those of us living with the condition, but it would also lighten the call we make on the NHS and social care.

The phase 2 clinical trial and my participation in it, not only helped prove that ambroxol may be beneficial in the treatment of Parkinson's, but also gave me a sense of hope and excitement that progress is being made, and that a cure for Parkinson's is within reach.

Bev Maydon, Cure Parkinson's supporter




Pictured above: Mairead Cullen, ASPro-PD Trial Manager

// We are very excited to be getting closer to opening the ASPro-PD trial to recruitment. The trial will be a world-first in Parkinson's and if it is successful, it could mean we are one step closer to slowing the progression of the disease and improving the lives of people with Parkinson's.

Mairead Cullen, ASPro-PD trial manager, UCL

HOW TO DONATE

Complete the enclosed form to donate and return to us using the Freepost envelope provided. Or you can donate online using the QR code or by visiting cureparkinsons.org.uk/donateambroxol



We would also like to thank the early supporters of this trial including Pears Foundation, Rosetrees Trust, The TJH Foundation, Frank Brake Charitable Trust and those who have chosen to remain anonymous.

Cure³ 2023 - the most successful edition to date!



Pictured above: Cure Parkinson's trustee Lyndsey Isaacs with Cure³ curators Laura Culpan and Suzie Allen

Cure³ is a unique and renowned selling art exhibition, curated by Artwise and hosted by Bonhams London in support of Cure Parkinson's. January saw the launch of the fourth edition of the exhibition that comprised of an extensive list of acclaimed artists submitting works based in or around a 20cm³ perspex box. There were exciting new additions for 2023 of 2D pieces and for the first time, specially commissioned non-fungible tokens (NFTs) from seven generative artists.

We were delighted to announce that this January saw the most successful edition of Cure³ to date with the event raising just under £700,000, all profits of which will go directly to support our Parkinson's research. Prices ranged from £500 to £80,000, and we were thrilled to have works by 96 incredible artists including Tracey Emin, Hurvin Anderson, Mona Hatoum, Annie Morris and Sir Frank Bowling; and the launch event was co-hosted by Tim Marlow, Director of the Design Museum.

Since the first edition in 2017, Cure³ has become an eagerly anticipated art world event, and to date has raised over £1.9 million. Cure³ has also generated huge amounts of awareness with its publicity, reaching an estimated global audience in excess of 4.3 billion including broadcast features this year on SKY News, BBC News and GB News.

// Cure³ is having a large impact on our progress, generating over £1.9 million gross since the first event in 2017. The funds raised are helping us to support groundbreaking research with the potential to slow, stop or reverse the progression of Parkinson's, giving hope to the 10 million people globally living with the condition.

Will Cook, CEO, Cure Parkinson's

Thanks to the support and generosity of so many, including the Cure³ organising committee, Artwise, Bonhams, the artists and the supporters who attend and purchase the works, the funds raised by this event have helped us progress vital research into a cure.

To read more about this event and see this year's artworks please visit our website at cureparkinsons.org.uk/cure3-2023-recap or use the QR code below.



READ MORE

Summer fundraising

The warmer months are a great time to get outdoors and embrace new hobbies and activities, catch up with friends and family, or maybe plan an overseas adventure! Why not use this time to bring your local community together and fundraise for Parkinson's research?

Need a hand getting started? We're here to help! We've a whole host of ideas for some summer fundraising fun - so get in touch. Whatever you choose to do, be assured that every penny you raise will be helping us in our search to slow, stop or even reverse the progression of Parkinson's.

In August 2022, the Parker family held a 'Songs for a Summer Evening' event. Joined by two singing groups - the Marenzio Singers and Sing to Beat Parkinson's - they raised £2,400.

// We were blessed with a glorious summer evening and having sold tickets around 100 people gathered to enjoy drinks, share picnics and listen to the music. We also had a raffle of prizes donated by local businesses.


Caroline Parker, Cure Parkinson's supporter

You too could turn an outdoor gathering at home or in your local community into a fundraiser. Invite family, friends and neighbours - from sizzling sausages on the barbecue to an afternoon tea party under blossom and bunting; from a picnic for Parkinson's to the fun of a sports tournament. However you'd like to get involved, there are so many wonderful ways you can join our summer festival of fundraising.

For more inspiration or to chat with one of the team please visit our website at cureparkinsons.org.uk/summer-fundraising or use the QR code below where you can also download some fundraising materials to add a splash of colour to your event.



FIND OUT MORE



Running for a cure

Looking to run a race in support of Cure Parkinson's but unsure where to start? Our new partnership with Run for Charity makes it easy to find races local to you, across the UK.



Pictured above: Friends Ellie Foster, Phoebe Hennah and Katie Tyndall taking part in the TCS London Marathon in support of Cure Parkinson's

Find your local run

Whether you want to run a 10k, or take on an endurance obstacle course, we have something for you. Convince a friend to take part too and make it a team event! We now have a wide variety of races available across the UK through our new partnership with Run for Charity so, no matter where you're based, you can now grab your trainers and a Cure Parkinson's running vest and sign up to an event near you!

Please visit our website cureparkinsons.org.uk/events/find-your-local-run and search by location to find out what is happening in your area or use the QR code below.



FIND OUT MORE

Join Team Cure and run your marathon

If you already have a place for a marathon, we'd love you to join us! As a member of Team Cure, you'll receive:

- Help and support from our friendly fundraising crew
- A free Cure Parkinson's technical running vest and fundraising pack with top notch tips and tricks and resources
- Excited whoops and applause from the Team Cure cheering squad en route!
- Regular updates on how your support is bringing us closer to a cure

If you don't yet have a place, take a look at our upcoming marathons on the next page. Alternatively please visit our website at cureparkinsons.org.uk/run-with-us or use the QR code below to find out more.



FIND OUT MORE

Events calendar

Join us at one of our many events taking place over the next six months from spring to autumn 2023.

RESEARCH EVENTS

Quarterly webinar series (online):

7 June / 6 September

Autumn Research Update Meeting:

Details coming soon on our website

SPECIAL EVENTS

Question of Sport: 14 September

The Legends at Rugby, A Double Centenary Celebration: 18 November

RUNNING EVENTS

Cardiff Half Marathon: 1 October

Royal Parks Half Marathon: 8 October

Yorkshire Marathon: 15 October

Oxford Half Marathon: 15 October

CYCLING EVENTS

Raid Ventoux: 13-17 June

ALL YEAR ROUND CHALLENGES

£1,000 Challenge: Choose your own activity

Kiltwalk: Various dates and locations

The Ultra Challenge Series:

Various dates and locations

Tough Mudder: Various dates and locations

Overseas Challenges: Treks on various dates

FACEBOOK CHALLENGE EVENT

Our next Facebook challenge is taking place in autumn - watch this space!




JOIN AN EVENT



Fundraiser of the Year Award

We were delighted to announce the winner of our 2022 Fundraiser of the Year award as the remarkable Simon Cooper. Simon was instrumental in nominating Lloyd's syndicate AEGIS London as lead sponsor of Cure Parkinson's Coast-to-Coast-to-Cure cycle challenge in 2019, and in 2022 organised a 318 mile cycle challenge with his colleagues at Castel.



Pictured above: Simon Cooper during the Castel Office2Office ride in support of Cure Parkinson's

This award recognises a person who has gone 'above and beyond' to raise funds for Parkinson's, and over the years Simon has done just that. Simon, who was diagnosed with Parkinson's in 2017, works within the Lloyd's insurance market and successfully nominated Cure Parkinson's to be one of the company's charity partners. Since then Simon has been instrumental in gaining support for the charity, including getting AEGIS London to support the charity's Coast-to-Coast-to-Cure cycle challenge which helped raise an impressive £70,000 to support our work to find a cure for Parkinson's.

In 2022, Simon took on a new challenge: to organise and take part in an epic 318 mile cycle challenge tackling 2,588m of ascent and travelling through four countries in three days. Simon's colleagues at Castel joined him on the ride, starting at the Castel offices in London and ending at the Castel offices in Amsterdam, with everyone involved determined to raise as much

money as possible for our Parkinson's research. The team even designed their own cycling jersey for the challenge, featuring the logos of all the sponsors they managed to secure. With such strong connections in the insurance sector, they acquired sponsorship from an impressive 77 companies.

// The ride was a success on many levels, as we got 40 people together who didn't know each other beforehand and formed great friendships, raised a lot of money and I became as fit as I had been in five years – which could only be good for my Parkinson's. One of my unexpected benefits was being sponsored by old school friends that I hadn't spoken to in 40 years, and we have now rekindled those friendships.

Simon Cooper, Head of Underwriting Insight, AEGIS London

The team managed to raise a staggering £340,000 in total for Cure Parkinson's from sponsorships and individual fundraising, with most of the riders raising over £3,000 each.

// We are extremely grateful to Simon for his ongoing support of Cure Parkinson's. His determination and dedication to raise funds and awareness for the charity is remarkable."

Will Cook, CEO, Cure Parkinson's

Corporate Partnerships

Support from companies not only helps us fund crucial research, but also raises awareness of Parkinson's and the impact it has on people's lives. We were delighted when The Good, The Bad & The Rugby and the Budy Smuggler team got together and created their own quirky new line of swimwear to support Cure Parkinson's vital research work!



Pictured above: The Good, The Bad & The Rugby and the Budy Smuggler's quirky new line of swimwear

You probably caught rugby legend and Cure Parkinson's patron Mike Tindall entertaining us from the I'm a Celebrity jungle last year. You may have even caught him wearing some revealing swimwear for a dip in the camp creek.

Australian-based swimwear company Budy Smuggler definitely noticed this and wasted no time in making their own special edition swim briefs. Working with Mike's rugby podcast The Good, The Bad & The Rugby, Budy Smuggler designed the cheeky swimwear based on some of Mike's infamous stories told in the jungle, with proceeds coming directly to Cure Parkinson's. After just a few weeks of sales, these limited edition Smugglers raised £1,600!

How you can get involved

At Cure Parkinson's we love working with companies of all sizes and sectors.

Whether you are a household brand or a new start-up, there are opportunities for you to help us cure Parkinson's. If you want to raise money from sales of a product, take on a challenge as a team or fundraise in your workplace we'd love to hear from you so please get in touch!

For more information please visit our website at cureparkinsons.org.uk/corporate-partnerships or use the QR code below. Alternatively please call Kelly on +44 (0)20 7487 3892 or email kelly@cureparkinsons.org.uk.



FIND OUT MORE

Coming up NEXT

In August, don't miss our exclusive bouquet created by NEXT flowers. For the entire month, proceeds from this 'Charity of the Month' Cure Parkinson's bouquet will go to us. To find out more and be kept up to date with all our fundraising news please sign up to receive our monthly newsletter on our website home page cureparkinsons.org.uk



Trusts and foundations

Does your trust want to support an organisation that is changing the face of neurological research? Or, how about one that has funded and significantly contributed to the development of more than a third of all disease-modifying (curative) trials worldwide?

Our trust and foundation partners play an incredibly important role in our work. Together, we are able to support more research projects which have the potential to slow, stop or reverse Parkinson's. By providing multi-year funding, our trust partners enable us to strategically plan for the future.

We are delighted to share that we have been awarded a grant of £200,000 from the Rosetrees Trust, co-funded by The Stoneygate Trust.

This gift will support the ground-breaking ASPro-PD trial which will be investigating the potential for the drug amroxol to slow the progression of Parkinson's. The funding will specifically help to support the recruitment of the Senior Research Fellow - a vital role within this. By investing in this trial, Rosetrees are helping us move ever closer to our goal of finding a cure for Parkinson's. We are incredibly excited to work with Rosetrees and Stoneygate over the next three years.

// Rosetrees Trust, together with our co-donor The Stoneygate Trust, are delighted to be partnering with Cure Parkinson's on the forthcoming clinical trial investigating whether amroxol can slow progression in Parkinson's. This is a very exciting opportunity to participate in a ground-breaking clinical trial that could directly impact people with Parkinson's.

Vineeth Rajkumar PhD, Head of Research, Rosetrees Trust

Who are the Rosetrees Trust?

Nat and Teresa Rosenbaum founded the Rosetrees Trust as a charity in 1987 as a way to give back to society. For over 30 years, they have been supporting cutting edge medical research. Their main aim is to improve the health and wellbeing of people with a focus on testing new ideas across the spectrum of medical research to bring the earliest possible benefit.

Over 360 projects are currently supported, from seedcorn 'out of the box' research ideas to large awards. Together with their co-funders they have awarded more than £1.04bn in grants.

Help fund ground-breaking Parkinson's research

If you represent a trust or foundation that would like to support vital research into drugs which show strong potential to cure this debilitating condition, please contact Melissa on +44 (0)20 7487 3892 or email melissa@cureparkinsons.org.uk

We understand that you want your donation to have the biggest impact possible. That's why your trust can choose to support the research which most closely aligns with your interests and goals. Gifts can support specific projects such as one of our International Linked Clinical Trials (iLCT), or of course, you can support our research in a more general sense.

Simply by supporting Cure Parkinson's, your trust will be accelerating research into a Parkinson's cure. Every donation makes a difference.

Leave a Legacy to Cure Parkinson's

By remembering Cure Parkinson's in your Will, you can help us transform the lives of millions of people around the world living with Parkinson's, now and in the future. In every new research trial, in every exciting breakthrough, your kindness will live on.

Step-by-step guide to leaving a gift to us in your Will

1. **Request your free Wills guide** online by visiting cureparkinsons.org.uk/leave-a-gift-in-your-will or email us at info@cureparkinsons.org.uk or write to us at:

Fundraising Team
Cure Parkinson's
120 New Cavendish Street
London W1W 6XX

2. **Find a solicitor or Will writer** and write or update your Will.

3. **Get in touch.** Please let us know if you have kindly left a gift for Cure Parkinson's in your Will.

4. **Join our Planting for a Cure campaign** and one of our trees will be dedicated to you or your loved one. Please visit cureparkinsons.org.uk/planting-for-a-cure

Pledge today and join the dozens of supporters who are committed to delivering a brighter future for people living with Parkinson's.



CURE
PARKINSON'S

Join the conversation

We'd love to tell you about what we're up to, and the most cost-effective way of doing this is by email. We promise that we will not fill your inbox with endless emails. You can change how you choose to hear from us at any time by visiting cureparkinsons.org.uk/your-permissions

You can also join us online on



120 New Cavendish Street, London W1W 6XX

amrc
ASSOCIATION OF MEDICAL RESEARCH CHARITIES



Cure Parkinson's is the operating name of The Cure Parkinson's Trust. The Cure Parkinson's Trust is a registered charity in England and Wales (1111816) and Scotland (SCO44368) and a company limited by guarantee - company number 05539974 (England and Wales).